Led by $355.38m acquisition of Beijing Wandong Medical Technology , Asia-Pacific’s medical devices industry saw a drop of 34.55% in deal activity during Q1 2021, when compared to the last four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

 

A total of 72 deals worth $1.48bn were announced for the region during Q1 2021, against the last four-quarter average of 110.00 deals.

Of all the deal types, venture financing saw most activity in Q1 2021 with 55 deals, representing a 76.4% share for the region.

In second place was M&A with 14 deals, followed by private equity deals with three transactions, respectively capturing a 19.4% and 4.2% share of the overall deal activity for the quarter.

In terms of value of deals, venture financing was the leading category in Asia-Pacific’s medical devices industry with $912.88m, while M&A and private equity deals totalled $382.93m and $183.33m, respectively.

Asia-Pacific medical devices industry deals in Q1 2021: Top deals

The top five medical devices deals accounted for a 59.5% share of the overall value during Q1 2021.

The combined value of the top five deals stood at $879.38m, against the overall value of $1.48bn recorded for the quarter.

The top five medical devices industry deals of Q1 2021 tracked by GlobalData were:

1) Midea Group’s $355.38m acquisition of Beijing Wandong Medical Technology

2) The $181.4m private equity deal with PHC by L Catterton Partners

3) ABC International , CCBI Tech Venture , Shiyu Capital Group , Sunland Capital , Thermo Fisher Scientific and YF Capital ’s $150m venture financing of WuXi Diagnostic Investment (Cayman )

4) The $100m venture financing deal with NewMed Medical by Boyuan Capital , Dachen Caizhi , Junzi Capital , Orbimed Advisors, Temasek Holdings (Private), Yunfeng Capital and Zhang Kelingyi

5) Alwin Capital , BioTrack Capital , Kangji Medical Holdings, LYFE Capital , Poly (Hengqin) Capital Management, Sanzheng Health Investment , Shanghai Guohe Modern Service Industry Equity Investment Management and Vertex Ventures China’s venture financing with Shenzhen Jingfeng Medical Technology for $92.6m.